

1/30



PhenoSense™ HIV Resistance Test Vector




Fig. 1

BEST AVAILABLE COPY

2/30

PhenoSense™ Schematic Diagram




Fig. 2

3/30




Fig. 3A

4/30





Fig. 3B

5/30



IDV-Control $IC_{50} = 0.0062$
 IDV-Patient $IC_{50} = 0.2935$ (47.4-fold)

Fig. 3C

6/30




Fig. 4A




Fig. 4B

7/30




Fig. 4C




Fig. 4D

8/30




Fig. 4E

9/30




Fig. 5A




Fig. 5B

10/30




Fig. 5C




Fig. 5D

11/30




Fig. 5E

12/30




Fig. 6A




Fig. 6B

14/30




Fig. 6C

15/30




Fig. 6D

16/30




Fig. 6E

17/30




Fig. 6F

18/30




Fig. 6G

19/30

Relation of NRTI and NNRTI Resistance to Replication Capacity




Fig. 6H

20/30

**Low Replication Capacity is Associated with High
Numbers of Mutations in Protease and L90M**




Fig. 6I

21/30

Low Replication Capacity is Associated with Specific Protease Mutations





Fig. 6J

22/30



%p41 in virions

Fig. 6K

23/30

Mutations in PR Associated with Gag Processing Defects




Fig. 6L

24/30

Patient Virus Reversion to Drug Susceptibility After Treatment Interruption

NRTI					NNRTI					PI				
WEEK	AZT	3TC	D4T	ABC	NVP	DLV	EFV	SQV	IDV	RTV	NFV	AMP		
day 0	3.7	>100	2.8	19	>300	88	115	85	72	73	74	16		
1	4.5	>100	3.3	20	>300	78	134	95	74	59	80	21		
2	5.8	>100	3.2	14	>300	75	142	89	77	49	59	19		
3	6.5	>100	2.7	15	>300	96	183	59	75	52	51	15		
4	6.3	>100	3.1	15	>300	94	174	59	68	50	49	15		
5	6.4	>100	3.0	17	>300	76	119	59	60	54	36	10		
6	5.0	>100	2.8	19	>300	93	168	89	39	80	40	18		
7	9.1	>100	4.1	12	>300	89	154	85	78	53	53	19		
9	2.8	8.1	1.9	5.0	22	15	10	1.8	3.5	4.7	4.0	2.0		
10	1.5	1.7	1.1	1.3	1.7	2.0	1.6	0.9	1.6	1.9	1.8	1.6		
11	0.9	1.2	1.0	1.2	0.8	1.1	0.9	1.0	1.1	1.1	1.1	1.0		
12	0.8	1.3	0.8	1.2	0.5	1.0	0.8	0.8	0.8	0.9	1.1	0.8		
23	0.7	1.1	1.0	0.6	0.8	1.1	0.8	0.8	0.8	1.0	0.9	0.6		

Fig. 6M

25/30





Fig. 6N

26/30

Fitness on GCRC STI Samples (wk 0 and 12)-Assay #2 RLU Corrected for p24 Input (% of Control)



27/30 .

To Measure Replication Capacity of Patient-Derived Viruses




Fig. 6P

28/30

To Measure Replication Capacity of Patient-Derived Recombinant Viruses




Fig. 6Q

29/30




Fig. 7

30/30




Fig. 8

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☒ FADED TEXT OR DRAWING

☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☐ LINES OR MARKS ON ORIGINAL DOCUMENT

☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.